Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin:
Boehringer Ingelheim, Bayer Health Care, Pfizer, Sanofi-Aventis, Novartis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harenberg, J., Nitschmann, S. Neue Wirkstoffe zur Thromboembolieprophylaxe. Internist 50, 757–760 (2009). https://doi.org/10.1007/s00108-009-2390-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-009-2390-2